{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:22:59Z","timestamp":1793748179214,"version":"4.6.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115750","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:19:08Z","timestamp":1692789548000},"page":"115750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023"],"prefix":"10.1016","volume":"260","author":[{"given":"Meibo","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115750_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41586-019-1605-5","article-title":"Cyclic GMP-AMP signalling protects bacteria against viral infection","volume":"574","author":"Cohen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/cmi.2015.95","article-title":"Molecular mechanisms regulating NLRP3 inflammasome activation","volume":"13","author":"Jo","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41577-022-00682-8","article-title":"Organellar homeostasis and innate immune sensing","volume":"22","author":"Harapas","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib5","first-page":"217","article-title":"How inflammasomes inform adaptive immunity","volume":"430","author":"Charles","year":"2018","journal-title":"J. Med. Biochem."},{"key":"10.1016\/j.ejmech.2023.115750_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-cellbio-101011-155745","article-title":"Inflammasomes and their roles in health and disease","volume":"28","author":"Lamkanfi","year":"2012","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib7","first-page":"588","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat. Rev."},{"key":"10.1016\/j.ejmech.2023.115750_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","article-title":"NLRP3 inflammasome in cancer and metabolic diseases","volume":"22","author":"Sharma","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111822","article-title":"Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases","volume":"185","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-\u03b2","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2023.115750_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"Schroder","year":"2010","journal-title":"The inflammasomes, Cell"},{"key":"10.1016\/j.ejmech.2023.115750_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12296","article-title":"Regulation of inflammasome activation","volume":"265","author":"Man","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejmech.2023.115750_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tibs.2022.10.002","article-title":"The NLRP3 inflammasome: activation and regulation","volume":"48","author":"Xu","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-Activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41419-019-2157-1","article-title":"NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-\u03baB signaling","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2023.115750_bib19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2023.115750_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","article-title":"Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 Expression","volume":"183","author":"Bauernfeind","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/JLB.3MR0720-513R","article-title":"NLRP3 inflammasome priming: a riddle wrapped in mystery inside an enigma","volume":"108","author":"McKee","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib24","doi-asserted-by":"crossref","first-page":"36617","DOI":"10.1074\/jbc.M112.407130","article-title":"Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation","volume":"287","author":"Juliana","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib25","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1084\/jem.20160933","article-title":"NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain","volume":"214","author":"Stutz","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.565924","article-title":"Priming is Dispensable for NLRP3 inflammasome activation in human monocytes","volume":"11","author":"Gritsenko","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","article-title":"K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter","volume":"38","author":"Planillo","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115750_bib28","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.4049\/jimmunol.175.11.7623","article-title":"Inhibitory effects of chloride on the activation of caspase-1, IL-1\u03b2 secretion, and cytolysis by the P2X7 receptor","volume":"175","author":"Verhoef","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature11588","article-title":"The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP","volume":"492","author":"Lee","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/ni.1631","article-title":"Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization","volume":"9","author":"Hornung","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/ni.1633","article-title":"Superoxide dismutase 1 regulates caspase-1 and endotoxic shock","volume":"9","author":"Meissner","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2012.01.009","article-title":"Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis","volume":"36","author":"Shimada","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115750_bib33","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1016\/j.cell.2021.11.011","article-title":"NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation","volume":"184","author":"Andreeva","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115750_bib34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10753-021-01439-6","article-title":"The signaling pathways regulating NLRP3 inflammasome activation","volume":"44","author":"Chen","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2023.115750_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cell.2017.01.008","article-title":"SnapShot: the noncanonical inflammasome","volume":"168","author":"Ding","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115750_bib39","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/eji.201545523","article-title":"Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells","volume":"45","author":"Schmid-Burgk","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib40","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nature15541","article-title":"Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling","volume":"526","author":"Kayagaki","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature13683","article-title":"Inflammatory caspases are innate immune receptors for intracellular LPS","volume":"514","author":"Shi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.115750_bib42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2023.115750_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","article-title":"Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space","volume":"64","author":"Schwaid","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2023.2239502","article-title":"A patent review of NLRP3 inhibitors to treat autoimmune diseases","volume":"33","author":"Xu","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115750_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2023.5238","article-title":"Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)","volume":"51","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.abb.2018.11.013","article-title":"Development of covalent NLRP3 inflammasome inhibitors: chemistry and biological activity","volume":"670","author":"Bertinaria","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2023.115750_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.1109938","article-title":"The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors","volume":"13","author":"Zhan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib48","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/molecules27196213","article-title":"A selective review and virtual screening analysis of natural product inhibitors of the NLRP3 Inflammasome","volume":"27","author":"El-Sayed","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115750_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cytogfr.2021.03.003","article-title":"Biological functions of NLRP3 inflammasome: a therapeutic target in inflammatory bowel disease","volume":"60","author":"Song","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2023.115750_bib51","volume":"14","author":"Blevins","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115750_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109916","article-title":"NLRP3 inflammasome in depression: a review","volume":"117","author":"Roy","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115750_bib53","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2174\/0929867327666200123093544","article-title":"Recent progress on the discovery of NLRP3 inhibitors and their therapeutic potential","volume":"28","author":"Su","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib54","first-page":"173","article-title":"Rockets, radiosensitizers, and RRx-001: an origin story part I, Discov","volume":"21","author":"Oronsky","year":"2016","journal-title":"M\u00e9d."},{"key":"10.1016\/j.ejmech.2023.115750_bib55","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor, Cell","volume":"18","author":"Chen","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ejmech.2023.115750_bib56","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.7150\/ijms.76615","article-title":"Superficial venous-associated inflammation from direct IV administration of RRx-001 in rats","volume":"19","author":"Caroen","year":"2022","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-023-01838-z","article-title":"A review of rrx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammation","volume":"83","author":"Jayabalan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.115750_bib58","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ijrobp.2022.12.031","article-title":"PREVLAR: phase 2a Randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck Chemoradiotherapy","volume":"116","author":"Bonomi","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2023.115750_bib59","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s15010-022-01904-w","article-title":"DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function","volume":"51","author":"Madurka","year":"2023","journal-title":"Infection"},{"key":"10.1016\/j.ejmech.2023.115750_bib63","series-title":"Method of Treating Schnitzler's Syndrome Using Dapansutrile","author":"Dinarello","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115750_bib64","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115750_bib65","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/molecules26123534","article-title":"Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177 (dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction","volume":"26","author":"Aliaga","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115750_bib66","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S2665-9913(20)30065-5","article-title":"Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial","volume":"2","author":"Kluck","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ejmech.2023.115750_bib67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115750_bib68","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1073\/pnas.2009680117","article-title":"The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of alzheimer's disease","volume":"117","author":"Lonnemann","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115750_bib69","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/all.15164","article-title":"The NLRP3 inflammasome inhibitor, OLT1177\u00ae, ameliorates experimental allergic asthma in mice","volume":"77","author":"Lunding","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.ejmech.2023.115750_bib71","series-title":"Novel Substituted Sulfonylurea Derivatives as NLRP3 Modulators and Their Preparation","author":"Sharma","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115750_bib79","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.3390\/biomedicines10123056","article-title":"NLRP3-inflammasome inhibition with IZD334 does not reduce cardiac damage in a pig model of myocardial infarction","volume":"10","author":"Silvis","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2023.115750_bib80","series-title":"Preparation of Pyridopyrazole Heterocyclic Derivative and its Application in Treating Diseases by Inhibiting NLRP3","author":"Su","year":"2023"},{"key":"10.1016\/j.ejmech.2023.115750_bib83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-3565(24)29317-4","article-title":"Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors","volume":"299","author":"Perregaux","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115750_bib84","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib85","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib86","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib87","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","article-title":"MCC950 closes the active conformation of NLRP3 to an inactive state","volume":"15","author":"Abellan","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2023.115750_bib89","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.115750_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib91","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/toxsci\/kfv152","article-title":"Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays","volume":"147","author":"Shah","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib92","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115750_bib93","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective NLRP3 Inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib94","first-page":"22","article-title":"Development of renal function tests for measurement of urine concentrating ability, urine acidification, and glomerular filtration rate in female cynomolgus monkeys","volume":"42","author":"Weekley","year":"2003","journal-title":"Contemp. Top. Lab. Anim. Sci."},{"key":"10.1016\/j.ejmech.2023.115750_bib95","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/acs.jmedchem.2c00149","article-title":"Synthesis and pharmacological evaluation of new N-sulfonylureas as NLRP3 inflammasome inhibitors: identification of a hit compound to treat gout","volume":"65","author":"Fern\u00e1ndez","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib96","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1021\/acs.jmedchem.3c00175","article-title":"Novel aryl sulfonamide derivatives as NLRP3 inflammasome inhibitors for the potential treatment of cancer","volume":"66","author":"Albanese","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib97","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cmdc.201700270","article-title":"Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors","volume":"12","author":"Hill","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115750_bib98","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/acsmedchemlett.9b00433","article-title":"Discovery of N-cyano-sulfoximineurea derivatives as potent and orally bioavailable NLRP3 inflammasome inhibitors","volume":"11","author":"Agarwal","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115750_bib99","article-title":"Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors","volume":"30","author":"Harrisona","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115750_bib100","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1021\/acs.jmedchem.0c01924","article-title":"Development of novel tetrahydroquinoline Inhibitors of NLRP3 inflammasome for potential treatment of DSS-induced mouse colitis","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib101","first-page":"316","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115750_bib102","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115750_bib103","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's Disease","volume":"55","author":"Yin","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2023.115750_bib104","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib105","doi-asserted-by":"crossref","first-page":"9718","DOI":"10.1021\/acs.jmedchem.9b01155","article-title":"Discovery of second-generation NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization","volume":"62","author":"Jiang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114468","article-title":"Development of sulfonamide-based NLRP3 inhibitors: further modifications and optimization through structure-activity relationship studies","volume":"238","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib107","doi-asserted-by":"crossref","first-page":"11985","DOI":"10.1021\/acs.jmedchem.2c00523","article-title":"Discovery of a novel oral proteasome inhibitor to block NLRP3 inflammasome activation with anti-inflammation activity","volume":"65","author":"Wu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114194","article-title":"Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis","volume":"232","author":"Jiao","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib109","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2023.115750_bib110","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2023.115750_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113417","article-title":"Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities","volume":"219","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib112","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cmdc.201600055","article-title":"Design, synthesis, and evaluation of acrylamide derivatives as direct nlrp3 inflammasome inhibitors","volume":"11","author":"Cocco","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2023.115750_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106010","article-title":"Design, synthesis and biological evaluation of phenyl vinyl sulfone based NLRP3 inflammasome inhibitors","volume":"128","author":"Zhang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127021","article-title":"Discovery and optimization of 4-oxo-2-thioxo-thiazolidinones as NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inhibitors","volume":"30","author":"Chen","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115750_bib116","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115750_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128693","article-title":"Design and synthesis of an N-benzyl-5-(4-sulfamoylbenzylidene-2-thioxothiazolidin)-4-one scaffold as a novel NLRP3 inflammasome inhibitor","volume":"65","author":"Zuo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115750_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128160","article-title":"Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity","volume":"46","author":"Chen","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.115750_bib119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00044-019-02466-7","article-title":"Design, synthesis, and screening of sulfonylurea-derived NLRP3 inflammasome inhibitors","volume":"29","author":"Kulkarni","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2023.115750_bib120","article-title":"Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation","volume":"58","author":"Zhang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib121","article-title":"An RRx-001 Analogue with potent anti-NLRP3 inflammasome activity but without high-energy nitro functional Groups","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115750_bib122","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1021\/acs.jmedchem.6b01624","article-title":"Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease","volume":"60","author":"Cocco","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib123","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.abb.2018.12.031","article-title":"Application of immobilized ATP to the study of NLRP inflammasomes","volume":"670","author":"Liao","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2023.115750_bib124","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.3390\/molecules26133975","article-title":"Chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor","volume":"26","author":"Gastaldi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115750_bib125","doi-asserted-by":"crossref","first-page":"13633","DOI":"10.1021\/acs.jmedchem.1c01007","article-title":"Discovery of novel pterostilbene-based derivatives as potent and orally active NLRP3 inflammasome inhibitors with inflammatory activity for colitis","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114357","article-title":"Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis","volume":"236","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106429","article-title":"Discovery of pterostilbene analogs as novel NLRP3 inflammasome inhibitors for potential treatment of DSS-induced colitis in mice","volume":"133","author":"Ruan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib128","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1021\/acs.jmedchem.2c01967","article-title":"Scaffold Hybrid of the natural product tanshinone I with piperidine for the discovery of a potent NLRP3 inflammasome inhibitor","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105536","article-title":"Identification of NLRP3 as a covalent target of 1,6-O,O-diacetylbritannilactone against neuroinflammation by quantitative thiol reactivity profiling (QTRP)","volume":"119","author":"Wang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib130","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong antiinflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115750_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114919","article-title":"Development of novel oridonin analogs as specifically targeted NLRP3 inflammasome inhibitors for the treatment of dextran sulfate sodium-induced colitis","volume":"245","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib132","article-title":"Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors","volume":"132","author":"Cofrade","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104363","article-title":"Limonoids from Toona ciliata: isolation, structural elucidation, and bioactivity against NLRP3 inflammasome","volume":"105","author":"Shi","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105971","article-title":"Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome","volume":"127","author":"Niu","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115750_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106534","article-title":"Abietane diterpenoids from Orthosiphon wulfenioides with NLRP3 inflammasome inhibitory activity","volume":"136","author":"Tu","year":"2023","journal-title":"Bioorg. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423007171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:56:51Z","timestamp":1759330611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423007171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":122,"alternative-id":["S0223523423007171"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115750","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115750"}}